Compare VVR & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | ENTA |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 377.5M |
| IPO Year | 1998 | 2012 |
| Metric | VVR | ENTA |
|---|---|---|
| Price | $2.88 | $11.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.83 |
| AVG Volume (30 Days) | ★ 711.1K | 267.1K |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $2.84 | $10.20 |
| 52 Week High | $3.38 | $17.15 |
| Indicator | VVR | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 39.77 |
| Support Level | $2.84 | $10.86 |
| Resistance Level | $2.92 | $13.95 |
| Average True Range (ATR) | 0.03 | 0.60 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 25.00 | 5.76 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective is to provide a high level of current income, consistent with preservation of capital. The Trust seeks to achieve its objectives by investing in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions. The Trust borrows money for investment purposes, which may create the opportunity for enhanced return, but also should be considered a speculative technique and may increase the Trust's volatility.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.